Faber Logo
Skip to main content

Neil Campbell

Senior Counsel 

Neil is an experienced transactional attorney who counsels clients on an array of transactions relating to drug and medical device research, development and manufacturing.

Neil structures, drafts, and negotiates licensing and collaboration, academic agreements, technology evaluation agreements, and manufacturing and other service agreements, and regularly assists clients in navigating complex multinational supply chain and clinical trial arrangements for small molecule and biologic products, including cell and gene therapies.

Prior to his legal career, Neil spent a decade as a biomedical researcher. In that role, he gained a deep scientific and industry context that enables him to appreciate clients’ scientific development strategies and provide them with thoughtful and pragmatic counsel.

More about Neil

Life Sciences Transactions Associate

Reed Smith LLP

Representation of public and private pharmaceutical and biotechnology companies, ranging from startups to multinational corporations in the US, Europe, and Japan, in a broad range of life sciences transactional matters.

Preclinical Imaging Shared Resource Manager

Rutgers Cancer Institute of New Jersey

Manufacturing and R&D Agreements

  • Drafted and negotiated multiple complex development and manufacturing agreements for CAR-T product supply chain of clinical-development stage company client
  • Represented early-stage drug development accelerator company in development and supply agreements for its gene therapy treatment for a rare genetic disorder
  • Drafted and negotiated sponsored research and other agreements with academic institutions in the USA, EU, and UK
  • Provided strategic legal counseling to multiple drug development companies in connection with large, multicenter, global Phase 2 and 3 clinical studies for small molecule and biologic products

Licensing and Collaboration Transactions

  • Multiple early-stage, venture-backed drug development companies in research collaborations to discover and/or generate multi-specific or conjugated antibodies directed against designated drug targets
  • EvolveImmune Therapeutics in a collaboration and option-to-license agreement with AbbVie to develop multi-specific biologics for multiple targets in oncology leveraging EvolveImmune’s T-cell engager platform, with an upfront payment of $65 million, up to $1.4 billion in option fees and milestones, as well as tiered royalty payments on net sales
  • TMS Co., Ltd. in a strategic collaboration agreement with JIXING Pharmaceuticals, subsequent to the assignment of TMS-007 global rights from Biogen to JIXING
  • ONK Therapeutics in a license and collaboration with Intellia to advance allogeneic CRISPR-Edited NK cell therapies, with milestones up to $920M plus royalties
  • Immunocore Holdings in a research and development collaboration with Gaeta B.V. to develop gamma delta (γδ) TCR-based immunotherapies for solid tumors, with an option for Immunocore to exclusively license candidates resulting from the collaboration
  • Alnylam in a License Agreement with Agios for novel siRNA for potential

Neil is a member of the Alumni Steering Committee for the Rutgers Center for Corporate Law and Governance.

Related Content

Previous Page
Next Page

Interested in working with Neil?

Our team is eager to learn more about your project

This site uses cookies. Some provide anonymous analysis of how our website is used and some are essential to make the website work. Other cookies enable personalized services or social media features to be used. By using our website, you agree to the use of cookies. To find out more, please see our Privacy Policy. You can disable cookies at any time by changing your browser settings.